Amylin and its role in appetite

What is amylin?

Amylin — formally islet amyloid polypeptide, or IAPP — is a 37-amino-acid peptide hormone made in the beta cells of the pancreas, the same cells that make insulin. When you eat, the two are released together, and amylin acts as a brake on the meal: it slows the rate at which the stomach empties, restrains the release of glucagon (the hormone that raises blood sugar), and sends a satiety signal to the brain (PMID 26071095).

For a long time amylin was best known for the wrong reason. In type 2 diabetes it can misfold and aggregate into the amyloid deposits that give the peptide its name, and that tendency to clump made native human amylin awkward to study and impossible to use as a medicine. Its physiological role as a satiety and glucose-regulating hormone — the reason it now matters for weight management — came into focus more slowly.

Co-secreted with insulin

The defining feature of amylin is that it does not travel alone. It is packaged and released with insulin from beta cells in roughly parallel fashion, so that a rise in insulin after eating is accompanied by a rise in amylin. This pairing is why amylin is often called insulin's partner hormone: insulin manages the fate of the glucose in a meal, while amylin manages the tempo of the meal itself — how quickly nutrients arrive and when eating stops.

That partnership also explains a clinical gap. In type 1 diabetes, the loss of beta cells removes not just insulin but amylin as well, so replacing insulin alone leaves the amylin side of the meal response unaddressed. This is the physiological logic behind developing an amylin analogue to use alongside insulin, rather than treating amylin as an afterthought (PMID 18561511).

How amylin signals fullness

Amylin's appetite effect is a brain effect. It acts on amylin receptors, which are not a single dedicated protein but a family assembled from the calcitonin receptor combined with receptor-activity-modifying proteins (RAMPs). A particularly important site of action is the area postrema, a region of the hindbrain that sits outside the blood-brain barrier and is well placed to sense circulating hormones. From there the signal is relayed through connected brainstem and hypothalamic circuits that shape how much and how long you eat (PMID 39426704).

Layered on top of that central satiety signal are amylin's peripheral actions — slowing gastric emptying and suppressing glucagon — which together smooth the rise in blood glucose after a meal and reinforce the sense of fullness. The combined picture is a hormone that works on both the gut's timing and the brain's meal-termination machinery, which is what makes its pathway attractive as a target for reducing food intake.

Amylin versus GLP-1

Amylin is frequently compared with GLP-1, the incretin hormone behind drugs such as semaglutide, because both curb appetite and both act partly through the hindbrain. But they are not the same switch. GLP-1 works through the GLP-1 receptor; amylin works through calcitonin-receptor-based amylin receptors. Reviews of the central circuitry describe amylin engaging satiety pathways that overlap with GLP-1's but are partly distinct, so activating one does not fully substitute for the other (PMID 39426704).

That partial independence is the whole strategic point of the amylin field. If two hormones reduce appetite through routes that only partly overlap, engaging both at once could add up to more than either alone — which is precisely the bet behind combining an amylin analogue with a GLP-1 agonist. You can read more about the incretin side of that pairing in our explainer on the GLP-1 receptor, and about the wider landscape in peptides for weight loss.

Pramlintide: the approved analogue

Native human amylin cannot be used as a drug because it aggregates. The solution was pramlintide, a synthetic analogue engineered with amino-acid substitutions — replacing residues prone to aggregation — that keep the molecule soluble and stable while preserving amylin's biological actions. For years it was the only amylin-based medicine on the market (PMID 18561511).

Pramlintide is approved as an adjunct to mealtime insulin in people with type 1 or type 2 diabetes. Given by subcutaneous injection alongside insulin, it slows gastric emptying, blunts the post-meal rise in glucagon and reduces food intake, and studies have documented modest reductions in body weight as part of that profile. Describing its approved role is not a dosing instruction: pramlintide is prescription-only, and how it is used in any individual is a clinical decision. Our dedicated summary on pramlintide goes deeper on the evidence.

Cagrilintide and CagriSema

Pramlintide proved the concept but had practical limits, including a short duration of action. The next step was an analogue that could be dosed once weekly. Cagrilintide is a long-acting amylin analogue developed with chemistry — including lipidation, the attachment of a fatty-acid chain that promotes albumin binding — that extends its time in the body and improves its stability compared with native amylin (PMID 34288673).

Cagrilintide is investigational for weight management and has been studied both on its own and in a fixed combination with the GLP-1 receptor agonist semaglutide. That combination, known as CagriSema, is the clearest expression of the amylin-plus-GLP-1 rationale: two satiety pathways engaged together. CagriSema is being evaluated in a programme of phase 3 obesity trials, including the REDEFINE 1 study, and is not an approved product at the time of writing. See our summary of cagrilintide for the molecule in detail.

What the pathway does not tell us

Understanding the amylin pathway explains why the target is attractive, but it does not settle the clinical questions that matter to a reader:

• Mechanism is not outcome. Knowing that amylin promotes satiety does not tell you how much weight any particular analogue produces, or how it compares with alternatives — those are questions for trials, not physiology.
• Approval status varies sharply. Pramlintide is approved only as an insulin adjunct in diabetes; long-acting analogues for obesity remain investigational. "Amylin" is not a single available treatment.
• Combination is a hypothesis under test. The idea that amylin plus GLP-1 beats either alone is being tested in ongoing trials; the pathway logic is suggestive, not proof.
• None of this is individualized guidance. Whether any drug that acts on this pathway is appropriate for a given person is a clinical judgement, not something the biology decides.

Held to that size, the amylin pathway is one of the more interesting stories in metabolic medicine: an old, overlooked partner hormone that turned out to have a druggable role in appetite, now being revisited with modern chemistry.

Frequently asked questions

Sources

This summary traces to peer-reviewed reviews and primary chemistry literature:

1. Amylin: Pharmacology, Physiology, and Clinical Potential — Pharmacological Reviews, 2015; PubMed 26071095.
2. Central nervous system pathways targeted by amylin in the regulation of food intake — Biochimie, 2025; PubMed 39426704.
3. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk — Vascular Health and Risk Management, 2008; PubMed 18561511.
4. Development of Cagrilintide, a Long-Acting Amylin Analogue — Journal of Medicinal Chemistry, 2021; PubMed 34288673.
5. Background reference record: amylin (islet amyloid polypeptide).

Related research